Several possible studies
Story checked
Novo's CagriSema shows 25% weight loss in women (opens in a new tab)
cnbc.com · 2026-10-20
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Novo's CagriSema shows 25% weight loss in women
cnbc.com · 2026-10-20
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Points somewhere elsepresented as the new finding
CagriSema 2.4 mg/2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedNovo said its next-generation obesity drug, CagriSema, showed 25% weight loss on average among adult women in a new analysis conducted after a late-stage trial.View evidenceHide evidence
As stated25% weight loss on average among adult women
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedNovo said further work is needed to confirm the hypotheses of the two post-study analyses, even as it framed the results as additional evidence that CagriSema may improve on the weight loss seen with semaglutide alone.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedIn an analysis of roughly 2,300 women with obesity or who were overweight, CagriSema was associated with 25% weight loss on average at 68 weeks compared with 3% with placebo, under an ideal scenario in which all patients stayed on treatment without interruptions.View evidenceHide evidence
As stated25% vs 3% at 68 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedA second analysis of around 1,900 women grouped by menopausal status found weight loss of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women at 68 weeks, compared with approximately 2% across menopause groups with placebo.View evidenceHide evidence
As stated26.7%, 24.8%, and 23.1% at 68 weeks
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedAcross both analyses, CagriSema was linked to reductions in abdominal fat, based on waist circumference, among women overall and across menopause stages.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
Frontiers in Endocrinology · 2026 · PubMed
The Effect of 6 Weeks of Body weight Exercises on the Respiratory Function of overweight Women
Advancement in Yoga and Physical Therapy · 2023 · Crossref
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
2026 · Europe PMC
Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.
Cureus · 2026 · PubMed
A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study
Obesity · 2012 · Crossref